AbbVie Inc.
AbbVie Inc. Completes Senior Notes Offering
Summary
On February 26, 2025, AbbVie Inc. completed its previously announced underwritten public offering of senior notes totaling $3.0 billion in aggregate principal amount. The offering included 4.650% senior notes due 2028, 4.875% senior notes due 2030, 5.200% senior notes due 2035, and 5.600% senior notes due 2055. The notes are governed by an indenture and are unsecured, unsubordinated obligations of AbbVie. The transaction was registered under the Securities Act of 1933 and further described in AbbVie's prospectus supplement. The legal documents related to the offering are provided as exhibits to this Form 8-K.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement